دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
A Special Thanks to the Reviewers of Diabetes Care
doi : 10.2337/dc21-en04
Diabetes Care 2021 Apr; 44(4): 855-857.
Resolving the Gestational Diabetes Diagnosis Conundrum: The Need for a Randomized Controlled Trial of Treatment
Rudolf W. Bilous1, Paul B. Jacklin2, Michael J. Maresh3 and David A. Sacks4?
doi : 10.2337/dc20-2941
Diabetes Care 2021 Apr; 44(4): 858-864.
The diagnosis of and criteria for gestational diabetes mellitus (GDM) continue to divide the scientific and medical community, both between and within countries. Many argue for universal adoption of the International Association of the Diabetes and Pregnancy Study Groups (IADPSG) criteria and feel that further clinical trials are unjustified and even unethical. However, there are concerns about the large increase in number of women who would be diagnosed with GDM using these criteria and the subsequent impact on health care resources and the individual. This Perspective reviews the origins of the IADPSG consensus and points out some of its less well-known limitations, particularly with respect to identifying women at risk for an adverse pregnancy outcome. It also questions the clinical and cost-effectiveness data often cited to support the IADPSG glycemic thresholds. We present the argument that adoption of diagnostic criteria defining GDM should be based on response to treatment at different diagnostic thresholds of maternal glycemia. This will likely require an international multicenter trial of treatment.
Association of Early-Phase In-Hospital Glycemic Fluctuation With Mortality in Adult Patients With Coronavirus Disease 2019
Liangkai Chen1, Wenwu Sun2, Yanli Liu2, Lijuan Zhang2, Yanling Lv1, Qiang Wang1, Ding Long2, Yujun Wang2, Su Zhao3, Shuang Rong4, Li Yu2? and Liegang Liu1?
doi : 10.2337/dc20-0780
Diabetes Care 2021 Apr; 44(4): 865-873.
OBJECTIVE To investigate the association of in-hospital early-phase glycemic control with adverse outcomes among inpatients with coronavirus disease 2019 (COVID-19) in Wuhan, China.
Cost-effectiveness of Community-Based Depression Interventions for Rural and Urban Adults With Type 2 Diabetes: Projections From Program ACTIVE (Adults Coming Together to Increase Vital Exercise) II
Shihchen Kuo1, Wen Ye1, Mary de Groot2?, Chandan Saha2, Jay H. Shubrook3,4, W. Guyton Hornsby Jr.5, Yegan Pillay6, Kieren J. Mather2 and William H. Herman1
doi : 10.2337/dc20-1639
Diabetes Care 2021 Apr; 44(4): 874-882.
OBJECTIVE We estimated the cost-effectiveness of the Program ACTIVE (Adults Coming Together to Increase Vital Exercise) II community-based exercise (EXER), cognitive behavioral therapy (CBT), and EXER+CBT interventions in adults with type 2 diabetes and depression relative to usual care (UC) and each other.
Association of Implementation of a Comprehensive Preconception-to-Pregnancy Management Plan With Pregnancy Outcomes Among Chinese Pregnant Women With Type 1 Diabetes: The CARNATION Study
Xueying Zheng1, Daizhi Yang2, Sihui Luo1, Jinhua Yan2, Xiaohui Guo3, Huixia Yang4, Wei Bao5, Leif Groop6, Anne Dornhorst7 and Jianping Weng1,2?, on behalf of the CARNATION Study Group*
doi : 10.2337/dc20-2692
Diabetes Care 2021 Apr; 44(4): 883-892.
OBJECTIVE To investigate the effect on pregnancy outcome of integrating a comprehensive management plan for patients with type 1 diabetes (T1D) into the World Health Organization universal maternal care infrastructure.
Examining the Relationship Between Delay Discounting, Delay Aversion, Diabetes Self-care Behaviors, and Diabetes Outcomes in U.S. Adults With Type 2 Diabetes
Jennifer A. Campbell1,2, Joni S. Williams1,2 and Leonard E. Egede1,2?
doi : 10.2337/dc20-2620
Diabetes Care 2021 Apr; 44(4): 893-900.
OBJECTIVE Delay discounting and delay aversion are emerging areas for understanding diabetes management; however, few data exist on their relationship with multiple diabetes self-care behaviors and diabetes outcomes.
A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes
Dorte Vistisen1?, Gregers S. Andersen1, Adam Hulman2, Stuart J. McGurnaghan3, Helen M. Colhoun3, Jan E. Henriksen4, Reimar W. Thomsen5, Frederik Persson1, Peter Rossing1,6 and Marit E. J?rgensen1,7
doi : 10.2337/dc20-2586
Diabetes Care 2021 Apr; 44(4): 901-907.
OBJECTIVE End-stage kidney disease (ESKD) is a life-threatening complication of diabetes that can be prevented or delayed by intervention. Hence, early detection of people at increased risk is essential.
Quantifying Variation in Treatment Utilization for Type 2 Diabetes Across Five Major University of California Health Systems
Thomas A. Peterson1, Valy Fontil2,3, Suneil K. Koliwad4,5, Ayan Patel6 and Atul J. Butte1,6?
doi : 10.2337/dc20-0344
Diabetes Care 2021 Apr; 44(4): 908-914.
OBJECTIVE Using the newly created University of California (UC) Health Data Warehouse, we present the first study to analyze antihyperglycemic treatment utilization across the five large UC academic health systems (Davis, Irvine, Los Angeles, San Diego, and San Francisco).
Glucose Control, Sulfonylureas, and Insulin Treatment in Elderly People With Type 2 Diabetes and Risk of Severe Hypoglycemia and Death: An Observational Study
Suping Ling1,2?, Francesco Zaccardi1,2, Claire Lawson1,2, Samuel I. Seidu1,2, Melanie J. Davies1,3 and Kamlesh Khunti1,2
doi : 10.2337/dc20-0876
Diabetes Care 2021 Apr; 44(4): 915-924.
OBJECTIVE To estimate the relative and absolute risk of severe hypoglycemia and mortality associated with glucose control, sulfonylureas, and insulin treatment in elderly people with type 2 diabetes.
Trends in Total and Out-of-pocket Payments for Noninsulin Glucose-Lowering Drugs Among U.S. Adults With Large-Employer Private Health Insurance From 2005 to 2018
Hui Shao1,2, Michael Laxy1,3, Stephen R. Benoit1, Yiling J. Cheng1, Edward W. Gregg1,4 and Ping Zhang1
doi : 10.2337/dc20-2871
Diabetes Care 2021 Apr; 44(4): 925-934.
OBJECTIVE To estimate trends in total payment and patients’ out-of-pocket (OOP) payments of noninsulin glucose-lowering drugs by class from 2005 to 2018.
Comparisons of Polyexposure, Polygenic, and Clinical Risk Scores in Risk Prediction of Type 2 Diabetes
Yixuan He1,2, Chirag M. Lakhani2, Danielle Rasooly2,3, Arjun K. Manrai2,3, Ioanna Tzoulaki4,5 and Chirag J. Patel2?
doi : 10.2337/dc20-2049
Diabetes Care 2021 Apr; 44(4): 935-943.
OBJECTIVE To establish a polyexposure score (PXS) for type 2 diabetes (T2D) incorporating 12 nongenetic exposures and examine whether a PXS and/or a polygenic risk score (PGS) improves diabetes prediction beyond traditional clinical risk factors.
Changes in the Diagnosis and Management of Diabetes in Mexico City Between 1998–2004 and 2015–2019
Diego Aguilar-Ramirez1, Jesus Alegre-D?az2, Louisa Gnatiuc1, Ra?l Ramirez-Reyes2, Rachel Wade1,3, Michael Hill1,3, Rory Collins1, Richard Peto1, Jonathan R. Emberson1,3?, William G. Herrington1,3, Pablo Kuri-Morales2 and Roberto Tapia-Conyer2
doi : 10.2337/dc20-2276
Diabetes Care 2021 Apr; 44(4): 944-951.
OBJECTIVE To investigate the trends in diabetes prevalence, diagnosis, and management among Mexican adults who were participants in a long-term prospective study.
Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial
Julie Dubourg1?, Pascale Fouqueray1, Carole Thang1, Jean-Marie Grouin2 and Kohjiro Ueki3
doi : 10.2337/dc20-0763
Diabetes Care 2021 Apr; 44(4): 952-959.
OBJECTIVE The aim of this study was to investigate the efficacy and safety of imeglimin, the first in a new class of oral antidiabetic agent, in Japanese patients with type 2 diabetes.
The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes
Klara R. Klein1?, Jennifer L.R. Freeman2, Imogene Dunn2, Chris Dvergsten2, M. Sue Kirkman1, John B. Buse1 and Carmen Valcarce2, on behalf of the SimpliciT1 research group*
doi : 10.2337/dc20-2684
Diabetes Care 2021 Apr; 44(4): 960-968.
OBJECTIVE Despite advances in exogenous insulin therapy, many patients with type 1 diabetes do not achieve acceptable glycemic control and remain at risk for ketosis and insulin-induced hypoglycemia. We conducted a randomized controlled trial to determine whether TTP399, a novel hepatoselective glucokinase activator, improved glycemic control in people with type 1 diabetes without increasing hypoglycemia or ketosis.
Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes
Olivia J. Collyns1, Renee A. Meier2, Zara L. Betts2, Denis S.H. Chan3, Chris Frampton4, Carla M. Frewen5, Niranjala M. Hewapathirana1, Shirley D. Jones5, Anirban Roy6, Benyamin Grosman6, Natalie Kurtz6, John Shin6, Robert A. Vigersky6, Benjamin J. Wheeler3,5 and Martin I. de Bock1,4?
doi : 10.2337/dc20-2250
Diabetes Care 2021 Apr; 44(4): 969-975.
OBJECTIVE To study the MiniMed Advanced Hybrid Closed-Loop (AHCL) system, which includes an algorithm with individualized basal target set points, automated correction bolus function, and improved Auto Mode stability.
Thresholds of Glycemia and the Outcomes of COVID-19 Complicated With Diabetes: A Retrospective Exploratory Study Using Continuous Glucose Monitoring
Yun Shen1, Xiaohong Fan2, Lei Zhang1, Yaxin Wang1, Cheng Li1, Jingyi Lu1, Bingbing Zha3, Yueyue Wu3, Xiaohua Chen4, Jian Zhou1? and Weiping Jia1?
doi : 10.2337/dc20-1448
Diabetes Care 2021 Apr; 44(4): 976-982.
OBJECTIVE Although elevated glucose levels are reported to be associated with adverse outcomes of coronavirus disease 2019 (COVID-19), the optimal range of glucose in patients with COVID-19 and diabetes remains unknown. This study aimed to investigate the threshold of glycemia and its association with the outcomes of COVID-19.
Impact of Type 1 Diabetes in the Developing Brain in Children: A Longitudinal Study
Nelly Mauras1?, Bruce Buckingham2, Neil H. White3, Eva Tsalikian4, Stuart A. Weinzimer5, Booil Jo6, Allison Cato7, Larry A. Fox1, Tandy Aye2, Ana Maria Arbelaez3, Tamara Hershey8, Michael Tansey4, William Tamborlane5, Lara C. Foland-Ross6, Hanyang Shen6, Kimberly Englert1, Paul Mazaika6, Matthew Marzelli6 and Allan L. Reiss2,6,9, for the Diabetes Research in Children Network (DirecNet)*
doi : 10.2337/dc20-2125
Diabetes Care 2021 Apr; 44(4): 983-992.
OBJECTIVE To assess whether previously observed brain and cognitive differences between children with type 1 diabetes and control subjects without diabetes persist, worsen, or improve as children grow into puberty and whether differences are associated with hyperglycemia.
Obstructive Sleep Apnea, Glucose Tolerance, and ?-Cell Function in Adults With Prediabetes or Untreated Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study
Babak Mokhlesi1?, Ashley H. Tjaden2, Karla A. Temple1, Sharon L. Edelstein2, Susan Sam1, Kristen J. Nadeau3, Tamara S. Hannon4, Shalini Manchanda4, Kieren J. Mather4, Steven E. Kahn5, David A. Ehrmann1 and Eve Van Cauter1, for the RISE Consortium*
doi : 10.2337/dc20-2127
Diabetes Care 2021 Apr; 44(4): 993-1001.
OBJECTIVE Obstructive sleep apnea (OSA) is associated with insulin resistance and has been described as a risk factor for type 2 diabetes. Whether OSA adversely impacts pancreatic islet ?-cell function remains unclear. We aimed to investigate the association of OSA and short sleep duration with ?-cell function in overweight/obese adults with prediabetes or recently diagnosed, treatment-naive type 2 diabetes.
Importance of Intestinal Environment and Cellular Plasticity of Islets in the Development of Postpancreatectomy Diabetes
Tatsuya Fukuda1, Ryotaro Bouchi1,2,3?, Takato Takeuchi1, Kikuko Amo-Shiinoki4, Atsushi Kudo5, Shinji Tanaka6, Minoru Tanabe5, Takumi Akashi7, Kazuhiro Hirayama8, Toshitaka Odamaki9, Miki Igarashi10, Ikuo Kimura10, Katsuya Tanabe4, Yukio Tanizawa4, Tetsuya Yamada1 and Yoshihiro Ogawa1,11,12,13?
doi : 10.2337/dc20-0864
Diabetes Care 2021 Apr; 44(4): 1002-1011.
OBJECTIVE To elucidate the pathogenesis of postpancreatectomy diabetes mellitus (PPDM).
Heart Rate and Heart Rate Variability Changes Are Not Related to Future Cardiovascular Disease and Death in People With and Without Dysglycemia: A Downfall of Risk Markers? The Whitehall II Cohort Study
Christian S. Hansen1,2?, Marit E. J?rgensen1, Marek Malik3,4, Daniel R. Witte2,5,6,7, Eric J. Brunner8, Adam G. Tab?k8,9,10, Mika Kivim?ki8 and Dorte Vistisen1
doi : 10.2337/dc20-2490
Diabetes Care 2021 Apr; 44(4): 1012-1019.
OBJECTIVE Higher resting heart rate (rHR) and lower heart rate variability (HRV) are associated with increased risk of cardiovascular disease (CVD) and all-cause mortality in people with and without diabetes. It is unknown whether temporal changes in rHR and HRV may contribute to this risk. We investigated associations between 5-year changes in rHR and HRV and risk of future CVD and death, taking into account participants’ baseline glycemic state.
Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial
Frederik Persson1?, Stephen C. Bain2, Ofri Mosenzon3,4, Hiddo J.L. Heerspink5, Johannes F.E. Mann6, Richard Pratley7, Itamar Raz3, Thomas Idorn8, S?ren Rasmussen8, Bernt Johan von Scholten8 and Peter Rossing1,9, on behalf of the LEADER Trial Investigators*
doi : 10.2337/dc20-1622
Diabetes Care 2021 Apr; 44(4): 1020-1026.
OBJECTIVE A post hoc analysis to investigate the association between 1-year changes in albuminuria and subsequent risk of cardiovascular and renal events.
Liraglutide Increases the Catabolism of Apolipoprotein B100–Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression
Bruno Vergès1,2?, Laurence Duvillard2,3, Jean Paul Pais de Barros2,4, Benjamin Bouillet1,2, Sabine Baillot-Rudoni1, Alexia Rouland1,2, Jean Michel Petit1,2, Pascal Degrace2 and Laurent Demizieux2
doi : 10.2337/dc20-1843
Diabetes Care 2021 Apr; 44(4): 1027-1037.
OBJECTIVE Dyslipidemia observed in type 2 diabetes (T2D) is atherogenic. Important features of diabetic dyslipidemia are increased levels of triglyceride-rich lipoproteins and small dense LDL particles, which all have apolipoprotein B100 (apoB100) as a major apolipoprotein. This prompted us to study the effect of the GLP-1 agonist liraglutide on the metabolism of apoB100-containing lipoproteins.
Association of Metabolic Phenotypes With Coronary Artery Disease and Cardiovascular Events in Patients With Stable Chest Pain
Andreas A. Kammerlander1,2?, Thomas Mayrhofer1,3, Maros Ferencik1,4, Neha J. Pagidipati5, Julia Karady1, Geoffrey S. Ginsburg6, Michael T. Lu1, Daniel O. Bittner1,7, Stefan B. Puchner1,8, Nathan A. Bihlmeyer9, Nandini M. Meyersohn1, Hamed Emami1, Svati H. Shah5,9, Pamela S. Douglas5 and Udo Hoffmann1, on behalf of the PROMISE Investigators
doi : 10.2337/dc20-1760
Diabetes Care 2021 Apr; 44(4): 1038-1045.
OBJECTIVE Obesity and metabolic syndrome are associated with major adverse cardiovascular events (MACE). However, whether distinct metabolic phenotypes differ in risk for coronary artery disease (CAD) and MACE is unknown. We sought to determine the association of distinct metabolic phenotypes with CAD and MACE.
Remote Continuous Glucose Monitoring With a Computerized Insulin Infusion Protocol for Critically Ill Patients in a COVID-19 Medical ICU: Proof of Concept
Georgia M. Davis1, Eileen Faulds2, Tara Walker3, Debbie Vigliotti4, Marina Rabinovich4, Joi Hester5, Limin Peng6, Barbara McLean7, Patricia Hannon7, Norma Poindexter7, Petrena Saunders7, Citlalli Perez-Guzman1, Seema S. Tekwani8, Greg S. Martin8, Guillermo Umpierrez1, Shivani Agarwal9, Kathleen Dungan2 and Francisco J. Pasquel1?
doi : 10.2337/dc20-2085
Diabetes Care 2021 Apr; 44(4): 1055-1058.
OBJECTIVE The use of remote real-time continuous glucose monitoring (CGM) in the hospital has rapidly emerged to preserve personal protective equipment and reduce potential exposures during coronavirus disease 2019 (COVID-19).
Rapid Changes in Serum Testosterone in Men With Newly Diagnosed Type 2 Diabetes With Intensive Insulin and Metformin
Yun Hu1, Bo Ding1, Yun Shen1, Reng-Na Yan1, Feng-Fei Li1, Rui Sun1, Ting Jing1, Kok-Onn Lee2 and Jian-Hua Ma1?
doi : 10.2337/dc20-1558
Diabetes Care 2021 Apr; 44(4): 1059-1061.
OBJECTIVE To investigate the effect of metformin on testosterone levels in men with type 2 diabetes mellitus (T2DM).
Accuracy of 1-Hour Plasma Glucose During the Oral Glucose Tolerance Test in Diagnosis of Type 2 Diabetes in Adults: A Meta-analysis
Vasudha Ahuja1?, Pasi Aronen2, T.A. Pramodkumar3, Helen Looker4, Angela Chetrit5, Aini H. Bloigu6, Auni Juutilainen7, Cristina Bianchi8, Lucia La Sala9, Ranjit Mohan Anjana3, Rajendra Pradeepa3, Ulagamadesan Venkatesan3, Sarvanan Jebarani3, Viswanathan Baskar3, Teresa Vanessa Fiorentino10, Patrick Timpel11, Ralph A. DeFronzo12, Antonio Ceriello9, Stefano Del Prato8, Muhammad Abdul-Ghani12, Sirkka Kein?nen-Kiukaanniemi6,13, Rachel Dankner5,14, Peter H. Bennett4, William C. Knowler4, Peter Schwarz11,15,16, Giorgio Sesti17, Rie Oka18, Viswanathan Mohan3, Leif Groop1,19, Jaakko Tuomilehto20,21,22, Samuli Ripatti1,23,24, Michael Bergman25 and Tiinamaija Tuomi1,19,26
doi : 10.2337/dc20-1688
Diabetes Care 2021 Apr; 44(4): 1062-1069.
OBJECTIVE One-hour plasma glucose (1-h PG) during the oral glucose tolerance test (OGTT) is an accurate predictor of type 2 diabetes. We performed a meta-analysis to determine the optimum cutoff of 1-h PG for detection of type 2 diabetes using 2-h PG as the gold standard.
Erratum. Health Care Utilization of Homeless Minors With Diabetes in New York State From 2009 to 2014. Diabetes Care 2020;43:2082–2089
Rie Sakai-Bizmark?, Laurie A. Mena, Dennys Estevez, Eliza J. Webber, Emily H. Marr, Lauren E.M. Bedel and Jennifer K. Yee
doi : 10.2337/dc21-er04
Diabetes Care 2021 Apr; 44(4): 1070-1070.
Erratum. Coronary Artery Disease and Type 2 Diabetes: A Proteomic Study. Diabetes Care 2020;43:843–851
Giulia Ferrannini, Maria Laura Manca, Marco Magnoni, Felicita Andreotti, Daniele Andreini, Roberto Latini, Attilio Maseri, Aldo P. Maggioni, Rachel M. Ostroff, Stephen A. Williams and Ele Ferrannini?
doi : 10.2337/dc21-er04a
Diabetes Care 2021 Apr; 44(4): 1071-1071.
Erratum. Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications. Diabetes Care 2021;44:390–398
Anita Jeyam, Helen Colhoun, Stuart McGurnaghan, Luke Blackbourn, Timothy J. McDonald, Colin N.A. Palmer, John A. McKnight, Mark W.J. Strachan, Alan W. Patrick, John Chalmers, Robert S. Lindsay, John R. Petrie, Sandeep Thekkepat, Andrew Collier, Sandra MacRury and Paul M. McKeigue?, on behalf of SDRNT1BIO Investigators
doi : 10.2337/dc21-er04b
Diabetes Care 2021 Apr; 44(4): 1072-1072.
How Common Is the Rare Charcot Foot in Patients With Diabetes?
Ole Lander Svendsen1,2,3?, Oliver Christian Rabe1,4, Matilde Winther-Jensen4 and Kristine H?jgaard Allin4,5
doi : 10.2337/dc20-2590
Diabetes Care 2021 Apr; 44(4): e62-e63.
Association Between DPP-4 Inhibitors and COVID-19–Related Outcomes Among Patients With Type 2 Diabetes
Yunha Noh1, In-Sun Oh1, Han Eol Jeong1, Kristian B. Filion2,3, Oriana Hoi Yun Yu3,4 and Ju-Young Shin1,5?
doi : 10.2337/dc20-1824
Diabetes Care 2021 Apr; 44(4): e64-e66.
Survival After Islet Transplantation in Subjects With Type 1 Diabetes: Twenty-Year Follow-Up
Joana R.N. Lemos1, David A. Baidal1,2, Camillo Ricordi1,3, Virginia Fuenmayor1, Ana Alvarez1 and Rodolfo Alejandro1,2?
doi : 10.2337/dc20-2458
Diabetes Care 2021 Apr; 44(4): e67-e68.
Comment on Tynj?l? et al. Arterial Stiffness Predicts Mortality in Individuals With Type 1 Diabetes. Diabetes Care 2020;43:2266–2271
José-Miguel Gonz?lez-Clemente1,2?, Gemma Llaurad?2,3, Albert Cano1, Olga Giménez-Palop1, Eugenia Berlanga4 and Joan Vendrell2,5
doi : 10.2337/dc20-2688
Diabetes Care 2021 Apr; 44(4): e69-e70.
Response to Comment on Tynj?l? et al. Arterial Stiffness Predicts Mortality in Individuals With Type 1 Diabetes. Diabetes Care 2020;43:2266–2271
Anniina Tynj?l?1,2,3, Carol Forsblom1,2,3, Valma Harjutsalo1,2,3,4, Per-Henrik Groop1,2,3,5? and Daniel Gordin1,2,3,6, on behalf of the FinnDiane Study Group
doi : 10.2337/dci20-0074
Diabetes Care 2021 Apr; 44(4): e71-e72.
Comment on Samara et al. Metformin Use Is Associated With Slowed Cognitive Decline and Reduced Incident Dementia in Older Adults With Type 2 Diabetes: The Sydney Memory and Ageing Study. Diabetes Care 2020;43:2691–2701
Jorge Rafael Violante-Cumpa, Luis Alberto Pérez-Arredondo, José Gerardo Gonz?lez-Gonz?lez and Leonardo Guadalupe Mancillas-Adame?
doi : 10.2337/dc20-2881
Diabetes Care 2021 Apr; 44(4): e73-e73.
Response to Comment on Samara et al. Metformin Use Is Associated With Slowed Cognitive Decline and Reduced Incident Dementia in Older Adults With Type 2 Diabetes: The Sydney Memory and Ageing Study. Diabetes Care 2020;43:2691–2701
Katherine Samaras1,2,3?, John D. Crawford4, Brian Draper4,5, Julian N. Trollor4,6, Henry Brodaty4,5 and Perminder S. Sachdev4,7
doi : 10.2337/dci20-0077
Diabetes Care 2021 Apr; 44(4): e74-e74.
Comment on H?skov? et al. Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial. Diabetes Care 2020;43:2744–2750
Alexander Seibold?
doi : 10.2337/dc20-2905
Diabetes Care 2021 Apr; 44(4): e75-e76.
Response to Comment on H?skov? et al. Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial. Diabetes Care 2020;43:2744–2750
Jan ?oupal?, Aneta H?skov? and Martin Pr?zn?
doi : 10.2337/dci20-0078
Diabetes Care 2021 Apr; 44(4): e77-e78.
Comment on Garofolo et al. Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. Diabetes Care 2020;43:e139–e141
José-Miguel Gonz?lez-Clemente1,2?, Gemma Llaurad?2,3, Lara Albert1, Olga Giménez-Palop1, Eugenia Berlanga4 and Joan Vendrell2,5
doi : 10.2337/dc20-2934
Diabetes Care 2021 Apr; 44(4): e79-e80.
Response to Comment on Garofolo et al. Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. Diabetes Care 2020;43:e139–e141
Monia Garofolo1, Elisa Gualdani2, Cristina Bianchi1, Michele Aragona1, Fabrizio Campi1, Daniela Lucchesi1, Giuseppe Daniele1, Roberto Miccoli1, Paolo Francesconi2, Stefano Del Prato1? and Giuseppe Penno1
doi : 10.2337/dci20-0079
Diabetes Care 2021 Apr; 44(4): e81-e81.
Association of Objectively Measured Timing of Physical Activity Bouts With Cardiovascular Health in Type 2 Diabetes
Jingyi Qian,1,2 Michael P. Walkup,3 Shyh-Huei Chen,3 Peter H. Brubaker,4 Dale S. Bond,5 Phyllis A. Richey,6 John M. Jakicic,7 Kun Hu,1,2 Frank A.J.L. Scheer,1,2 Roeland J.W. Middelbeek,8 and the Look AHEAD Research Group*
doi : 10.2337/dc20-2178
Diabetes Care 2021;44:1046–1054
Moderate- to vigorous-intensity physical activity (MVPA) improves cardiovascular health. Few studies have examined MVPA timing. We examined the associations of timing of bout-related MVPA with cardiorespiratory fitness and cardiovascular risk in adults with type 2 diabetes.
